Has OncuraKit been validated across diverse racial and ethnic populations?

The Yenos validation studies enrolled cancer patients and healthy controls but the specific demographic breakdown of the study population is not detailed in the published papers. One of the foundational claims of the Yenos platform is that miRNA levels — when normalized to total RNA content (the HL approach) — are consistent across age, sex, and ethnicity in healthy individuals. This claim is based on the biological observation that miRNA biogenesis and cancer-associated overexpression are fundamental cellular processes that operate similarly across populations. However, prospective validation in large, diverse populations representing all racial and ethnic groups is an important next step in the clinical development of OncuraKit. Any test user from any demographic should consult with their physician about their results.